New Guideline for Intra-Abdominal Infection Released

http://news.idsociety.org/idsa/issues/2010-01-31/2.html

IDSA guideline for Intra-abdominal infection released January 2010

TREAT

Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)

Gold Spirometry

GOLD SPIROMETRIC CRITERIA FOR COPD SEVERITY1
I: Mild COPD
• FEV1/FVC < 0.7
• FEV1 ≥ 80% predicted
At this stage, the patient may not be aware that their lung function is abnormal.

II: Moderate COPD
• FEV1/FVC < 0.7
• 50% ≤ FEV1 < 80%
predicted Symptoms usually progress at this stage, with shortness of breath typically developing on exertion.

III: Severe COPD
• FEV1/FVC < 0.7
• 30% ≤ FEV1 < 50% predicted
Shortness of breath typically worsens at this stage and often limits patients’ daily activities. Exacerbations are especially seen beginning at this stage.

IV: Very Severe COPD
• FEV1/FVC < 0.7
• FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failure
At this stage, quality of life is very appreciably impaired and exacerbations may be life-threatening.

GOLD

NCBI PubMED

http://www.ncbi.nlm.nih.gov/pubmed/

ABG Quiz

ABG Online Quiz

Take the quiz here

ATP III

Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults

JUPITER TRIAL

JUPITER trial (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin trial)
http://www.brighamandwomens.org/preventivemedicine/Research/Circv108p2292.pdf